Document is current
Any future updates will be listed below
-
Authors
Mazurek, Jeremy A.
Germack, Hayley D.
Gauthier-Loiselle, Marjolaine
Satija, Ambika
Manceur, Ameur M.
Shi, Sherry
Cloutier, Martin
Lefebvre, Patrick
Panjabi, Sumeet
-
Funding
Funding for this research was provided by:
Janssen Pharmaceuticals
- License Information
-
More Information
Article History
Received: 13 February 2024
Accepted: 17 February 2025
First Online: 10 April 2025
Declarations
:
: JAM has received research grants from Corvia Medical, Tenax Therapeutics, and Merck, and consultancy fees from Janssen Pharmaceuticals, United Therapeutics and Merck. HDG was an employee of Johnson and Johnson Innovative Medicines at the time that this study was conducted and may own stock/stock options. SP is an employee of Johnson and Johnson Innovative Medicines and may own stock/stock options. MGL, AS, AMM, SS, MC, and PL are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson and Johnson Innovative Medicines, which funded the development and conduct of this study and manuscript.
: Data were de-identified and comply with the patient requirements of the HIPAA of 1996; therefore, no review by an institutional review board was required per Title 45 of CFR, Part 46.101(b)(4) ().
